Skip to content

13F-HR filed by Versant Venture Management, LLC

Versant Venture Management, LLC filed this 13F-HR for the quarter ended 2020-09-30, filed 2020-11-12, with 11 holding rows worth $546,369,000.

Accession
0000950123-20-011532
Filed
2020-11-12
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2020

A holdings report, 11 entries on the cover page, a total value of $546,369,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $546,369,000 with VALUE read as thousands by filing date, 13F file number 028-16849. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
CRISPR THERAPEUTICS AG NAMEN AKTH17182108Stock3,631,656$303,752,000thousands by filing date
Adverum Biotechnologies, Inc.00773U108Common Stock7,003,892$72,140,000thousands by filing date
APREA THERAPEUTICS INC03836J102COM1,854,229$44,613,000thousands by filing date
FLEXION THERAPEUTICS INC33938J106COM3,842,578$40,001,000thousands by filing date
CRINETICS PHARMACEUTICALS INC COM22663K107Stock2,030,616$31,820,000thousands by filing date
AKERO THERAPEUTICS INC00973Y108COM777,727$23,946,000thousands by filing date
OCULAR THERAPEUTIX INC67576A100COM2,215,384$16,859,000thousands by filing date
GRITSTONE BIO INC39868T105COM3,102,929$8,223,000thousands by filing date
CYMABAY THERAPEUTICS INC23257D103COM543,753$3,937,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM101,855$594,000thousands by filing date
SECOND SIGHT MED PRODS INC81362J100COM561,612$484,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-20-011532this filing2020-11-12acceptance time not in the bulk data set